Skip to main content
. 2018 Jul 9;53(3):1118–1128. doi: 10.3892/ijo.2018.4475

Figure 4.

Figure 4

Cytoskeletal remodeling may be involved in PFN2-regulated EMT. (A and B) p-MLC expression was measured by western blotting in (A) normal colon, non-metastatic CRC and metastatic CRC tissues, and (B) in untransfected, vector- and PFN2-OE-transfected SW620 cells. (C) Protein expression levels of PFN2, p-MLC, E-cadherin and vimentin were examined by western blotting in PFN2-OE-transfected SW620 cells with or without co-treatment with Y27632; β-tubulin served as the internal reference. (D) Wound-healing assays were performed to determine the migratory ability of PFN2-OE-transfected SW620 with or without co-treatment with Y27632. Data are presented as the mean ± sandard error of the mean of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001. CRC, colorectal cancer; EMT, epithelial-mesenchymal transition; MLC, myosin light chain; OE, overexpression; p, phosphorylated; PFN2, profilin 2; Y, Rho-associated kinase inhibitor Y27632.